{"id":"aede6d7b-8df3-500e-a8b5-56e14a022c5b","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:two-months-of-supplementation-lowers-factor-viii","predicate":"reduces","statement":"Factor VIII declined by 17 to 19% over the same two months.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"ec907dcb-01da-530a-b45c-982757991457","mechanism_event_label":"Factor VIII declined by 17 to 19% over the same two months.","subject":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"object":{"id":"87d8ad0b-abcc-5313-8aa4-985eff05e6dd","slug":"f8","display_name":"Human coagulation factor VIII / F8","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"ec907dcb-01da-530a-b45c-982757991457","stable_key":"33bef151-bdc7-5892-aff6-0345ab149739:two-months-of-supplementation-lowers-factor-viii-event","event_type":"observed_intervention","label":"Factor VIII declined by 17 to 19% over the same two months.","description":"Plasma","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e8eb9bb4-3c6f-5e96-a968-a6d1fece71e7","slug":"nattokinase-supplement","display_name":"Commercial nattokinase supplement, composition study-specific","entity_type_key":"chemical_species"},"role":"acting component","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"87d8ad0b-abcc-5313-8aa4-985eff05e6dd","slug":"f8","display_name":"Human coagulation factor VIII / F8","entity_type_key":"protein"},"role":"component the finding is about","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"2 months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human (45 subjects across three groups)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nattokinase, 4,000 FU per day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"As above, and the largest of the three declines. It agrees in direction with the single-dose crossover result, which is a different design in a different population.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Human (45 subjects across three groups)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Factor VIII declined by 17 to 19% over the same two months.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. (2009) https://pubmed.ncbi.nlm.nih.gov/19358933/ DOI: 10.1016/j.nutres.2009.01.009","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vivo, oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Plasma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b2c7397f-deda-5a8a-880d-fc38bf7ce217","evidence_kind":"source_excerpt","locator":"Lines 939-939","start_line":939,"end_line":939,"excerpt":"Factor VIII declined by 17 to 19% over the same two months.","model_system":"Human (45 subjects across three groups)","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"41cb127c-1c23-53aa-b7d0-5ec7f6fa3c99","stable_key":"import-33bef151-bdc7-5892-aff6-0345ab149739","title":"Nattokinase: what the purified enzyme cleaves, what survives being eaten, and the gap between the two (2026-09-23)","document_type":"imported_text","citation_label":"Original AI-assisted curation built from a supplied entity-first document of 105 entities and 129 claims. Every reference in that document was resolved against live PubMed with its abstract read and its DOI cross-checked on 2026-09-23, and the EFSA novel-food opinion was retrieved and read in full. That check corrected two PMIDs that pointed at unrelated papers, two DOIs, and two papers recorded as carrying no erratum that do carry one; it also reversed three findings the supplied document had stated backwards. Two papers carry a published correction, recorded as such and not as a retraction. Three sources are not indexed in PubMed and are cited by what they have. Laboratory lineages are recorded, so the four papers from one group, the three from another and the two readings of a single applicant dossier cannot be counted as separate lines of support. Study-specific doses, units, populations and limitations retained; activity units are never converted between systems. Not publisher full text.","file_path":"","sha256":"34fc46e0e849d06bfa13cb099a79b50679dd6fd0de8a5a0575326afdde3259c1","revision_id":"efd063e6-e982-5f6e-a4b8-6f2ffe4185ce","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}